AIM Vaccine Past Earnings Performance
Past criteria checks 0/6
AIM Vaccine's earnings have been declining at an average annual rate of -47.2%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 2.4% per year.
Key information
-47.2%
Earnings growth rate
-48.2%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | -2.4% |
| Return on equity | -49.1% |
| Net Margin | -100.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt
Nov 15
Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge
Aug 24It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)
May 29Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking
Jun 09Revenue & Expenses Breakdown
How AIM Vaccine makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,184 | -1,190 | 768 | 408 |
| 31 Mar 24 | 1,186 | -1,245 | 760 | 522 |
| 31 Dec 23 | 1,187 | -1,301 | 752 | 636 |
| 30 Sep 23 | 1,200 | -913 | 821 | 671 |
| 30 Jun 23 | 1,213 | -525 | 890 | 705 |
| 31 Mar 23 | 1,239 | -422 | 931 | 603 |
| 31 Dec 22 | 1,264 | -320 | 971 | 500 |
| 31 Dec 21 | 1,570 | -693 | 1,636 | 307 |
| 31 Dec 20 | 1,638 | 379 | 733 | 158 |
| 31 Dec 19 | 952 | 117 | 485 | 99 |
Quality Earnings: 6660 is currently unprofitable.
Growing Profit Margin: 6660 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6660 is unprofitable, and losses have increased over the past 5 years at a rate of 47.2% per year.
Accelerating Growth: Unable to compare 6660's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6660 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 6660 has a negative Return on Equity (-49.09%), as it is currently unprofitable.